Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-054487
Filing Date
2021-04-23
Accepted
2021-04-23 16:33:04
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2113410d3_defa14a.htm DEFA14A 18692
2 GRAPHIC tm2113410d3_defa14aimg001.jpg GRAPHIC 226706
3 GRAPHIC tm2113410d3_defa14aimg002.jpg GRAPHIC 235573
  Complete submission text file 0001104659-21-054487.txt   656888
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37939 | Film No.: 21850248
SIC: 2834 Pharmaceutical Preparations